The Trippy Science of Psychedelic Studies

After I signed up for one, I started to dig into their data. That’s when things got weird.

Elitsa Dermendzhiyska
Elemental
Published in
12 min readAug 22, 2019

--

A photo of magic mushrooms, Psilocybe semilanceata, covered in frost.
Magic mushrooms, Psilocybe semilanceata, covered in frost. Photo: Andrew Hasson/Getty Images

I’I’ve never been the kind of person to gush about mind-altering drugs. In fact, it takes only the slightest whiff of woo-woo to send me rolling my eyes — hard, with gleeful abandon. But when I tell people I’ll be taking a not-insignificant dose of psychedelics as part of a research study to treat depression, no shock ensues.

We live in a psychedelic renaissance where tripping for divine revelation or high productivity is fast becoming a trend. But what really interests me is the scientists — in particular, those who talk about treating depression and dissolving the ego, all in the same breath.

The research team I’ve picked at Imperial College London (ICL) is one of a few exploring the potential for psychedelics to treat intractable mental illnesses. The results of their work so far have been impressive. For instance, in a 2016 study, all 12 of the volunteers (all of whom struggled with treatment-resistant depression) saw relief. Eight were depression-free after just one week, five of those stayed in remission, and two others sustained a significant reduction in symptoms at the three-month follow-up. Other psychedelic studies have shown similar promise in helping people with…

--

--

Elitsa Dermendzhiyska
Elemental

Social entrepreneur & editor of ‘What Doesn’t Kill You’ — deeply personal stories by 13 authors & thinkers https://amzn.to/3dFG683